Published in BMC Urol on May 31, 2012
Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg (2004) 55.13
The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg (2009) 16.82
Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis. Eur Urol (2007) 2.84
Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol (2008) 2.34
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
EAU guidelines on testicular cancer: 2011 update. Eur Urol (2011) 1.96
Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol (2007) 1.74
The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol (2008) 1.71
Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol (2004) 1.68
Advanced testicular cancer: update for urologists. J Urol (1998) 1.41
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery. J Urol (2009) 1.07
Postchemotherapy laparoscopic retroperitoneal lymph node dissection in nonseminomatous germ-cell tumor. J Endourol (2009) 1.07
Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. J Urol (2008) 1.02
Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 1.00
Complications of laparoscopic retroperitoneal lymph node dissection in testicular cancer. World J Urol (2008) 0.99
Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol Oncol (2008) 0.94
Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. Urology (2009) 0.92
Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int (2010) 0.92
Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol (2004) 0.90
Laparoscopic retroperitoneal lymph-node dissection in the management of clinical stage I and II testicular cancer. J Endourol (2005) 0.89
Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor. World J Surg Oncol (2010) 0.85
Postchemotherapy laparoscopic retroperitoneal lymph node dissection: evaluation of complications. Urology (2007) 0.82
Laparoscopic retroperitoneal lymph node dissection. J Endourol (2001) 0.81
Retroperitoneal laparoscopic lymph node dissection for staging non-seminomatous germ cell tumors before and after chemotherapy. Lymphology (1996) 0.80
Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 0.79
Laparoscopic retroperitoneal lymph node dissection: technique. BJU Int (2007) 0.77
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol (2009) 5.62
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer (2010) 4.53
Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol (2010) 4.11
Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. Retrovirology (2009) 4.11
The epidemiology of renal cell carcinoma. Eur Urol (2011) 3.85
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol (2013) 2.87
Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother (2009) 2.86
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol (2007) 2.79
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. J Urol (2010) 2.48
Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res (2007) 2.47
Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Clin Nutr (2008) 2.35
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol (2008) 2.29
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer. Urology (2009) 2.10
Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma. Eur Urol (2012) 2.10
N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort. Cancer Epidemiol Biomarkers Prev (2013) 2.01
Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem (2010) 1.99
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2013) 1.95
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol (2005) 1.93
Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol (2010) 1.82
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int (2009) 1.80
Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J Urol (2009) 1.77
The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol (2008) 1.71
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol (2012) 1.69
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol (2008) 1.68
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med (2005) 1.67
Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr (2012) 1.61
Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms. Clin Chem (2011) 1.59
Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis. Eur Urol (2013) 1.59
Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol (2011) 1.56
Retracted Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res (2008) 1.51
Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study. Strahlenther Onkol (2011) 1.45
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. Can J Urol (2012) 1.43
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn (2013) 1.30
Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version? Eur Urol (2010) 1.26
A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate (2009) 1.25
Metabolic profiling reveals key metabolic features of renal cell carcinoma. J Cell Mol Med (2011) 1.23
Radiotherapy and Hormone Treatment in Prostate Cancer. Dtsch Arztebl Int (2016) 1.21
MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urol Oncol (2008) 1.18
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer (2012) 1.16
Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci (2012) 1.14
Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer (2012) 1.14
Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem (2012) 1.14
Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev (2008) 1.12
Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards. Clin Chem Lab Med (2008) 1.12
Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med (2010) 1.10
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology (2009) 1.10
Reference miRNAs for miRNAome analysis of urothelial carcinomas. PLoS One (2012) 1.09
The German S3 guideline prostate cancer: aspects for the radiation oncologist. Strahlenther Onkol (2010) 1.09
Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. Eur J Cancer (2012) 1.08
Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol (2008) 1.07
Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin Cancer Res (2006) 1.06
Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clin Chim Acta (2012) 1.05
Localization of FOXP3-positive cells in renal cell carcinoma. Tumour Biol (2011) 1.05
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer (2010) 1.05